Vascular diseases account for one-third of all mortality in the U.S., Europe, and the developing world. In a study published in the American Journal of Pathology, researchers found that drugs targeting FXR1 (fragile-X related protein-1) may treat vascular proliferative diseases. Michael Autieri, PhD, Director and Professor in the Lemole Center for Integrated Lymphatics Research; Associate Director and Professor in the Cardiovascular Research Center; and Professor of Cardiovascular Sciences, in the Center for Metabolic Disease Research, in the Sol Sherry Thrombosis Research Center and in Biomedical Education and Data Science at the Lewis Katz School of Medicine at Temple University, was the lead investigator on the study. Scienmag and Newswise highlighted the findings.
Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First is scheduled to end on July 31st. Click the link below to learn about your options for continuing care at Temple Health.
Learn More
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH